Thermo Fisher Scientific Adds Digital PCR to Genetic Analysis Capabilities

Rhea-AI Summary

Thermo Fisher Scientific (NYSE: TMO) announced the launch of the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR system. This innovative technology aims to provide accurate and consistent results in just 90 minutes, enhancing applications in oncology and gene therapy. By acquiring Combinati's advanced dPCR technology, Thermo Fisher aims to expedite innovation in cancer research. The system simplifies workflows, reducing hands-on time to five minutes, minimizing user errors, and accelerating genetic analysis processes for biotech and academic institutions.

Positive

• Launch of the QuantStudio Absolute Q Digital PCR System enhances accuracy in genetic analysis.
• Acquisition of Combinati's dPCR technology strengthens research capabilities.
• Simplified workflows reduce hands-on time and user error, increasing efficiency.

Negative

• None.

WALTHAM, Mass., Sept. 20, 2021 /PRNewswire/ -- Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, today launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.

The QuantStudio Absolute Q  provides an industry-best dPCR platform accelerating innovation in cancer research and more.

dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy development and other research applications because its absolute quantification enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of assays.

The dPCR technology that powers the QuantStudio Absolute Q solution is already in use by biotech companies and academic institutions for longitudinal monitoring of cancer-driving mutations in liquid biopsy, precise quantification of gene inserts for cell therapy development, and copy number variation studies for earlier identification of genetic conditions in newborns.

"These early adopters of dPCR technologies have faced limitations, including error-prone operation, imprecision and poor turnaround times," said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. "For our customers, the QuantStudio Absolute Q Digital PCR System overcomes these limitations and provides an industry-best dPCR platform to enable accelerated innovation in cancer research, rare diseases and much more."

Philip Lee, Chief Technology Officer, Senti Biosciences said "Accurate measurement of genetic biomarkers is critical to Senti Biosciences' gene circuit technology. We adopted this novel solution for its fast and simple workflow, which makes a significant difference in generating consistent and accurate data quickly.  It was straightforward to implement, and new users can generate the data that we need with ease."

Unlike complex, multi-instrument workflows required for traditional dPCR, the QuantStudio Absolute Q System uses microfluidic array technology and simplified workflows, designed to improve data accuracy and consistency. Hands-on time is just five minutes, minimizing the risk of user error.

For more information, please visit www.thermofisher.com/digitalpcr.

* For research use only.  Not for use in diagnostic procedures

About Thermo Fisher Scientific 
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com. 

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada 
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/thermo-fisher-scientific-adds-digital-pcr-to-genetic-analysis-capabilities-301380061.html

SOURCE Thermo Fisher Scientific

FAQ

What is the Applied Biosystems QuantStudio Absolute Q Digital PCR System from Thermo Fisher?

The Applied Biosystems QuantStudio Absolute Q Digital PCR System is the first fully integrated digital PCR system that delivers accurate results in 90 minutes, designed for applications in oncology and gene therapy.

When was the QuantStudio Absolute Q Digital PCR System launched?

The QuantStudio Absolute Q Digital PCR System was launched on September 20, 2021.

How does the QuantStudio Absolute Q Digital PCR System improve genetic analysis?

The system enhances genetic analysis by providing higher accuracy and consistency, reducing hands-on time to five minutes, and minimizing user errors.

What impact does the acquisition of Combinati have on Thermo Fisher?

The acquisition of Combinati allows Thermo Fisher to rapidly develop and commercialize advanced dPCR technologies, enhancing its portfolio for cancer research and genetic analysis.

What are the applications of the QuantStudio Absolute Q Digital PCR System?

The system is ideal for oncology, cell and gene therapy development, and other research applications requiring precise quantification of genetic material.